Home » Market News » DirectorsTalk Highlights » Where Are the Manuals for Life?
Immupharma Plc

Where Are the Manuals for Life?

People tease about how there are no manuals for rearing kids. Well, there is no manual on how to navigate an illness like lupus, either. Everyone is simply winging it and hoping they are making the right decisions.

It seems lupus is always delivering something new, with no instructions on how to deal with it. With each new delivery comes extra parts that don’t fit. Without a manual, there’s no way to know if it’s put together correctly — until it falls apart.

Few AIM-listed drug development companies have late-stage clinical assets in the pipeline, ImmuPharma plc (LON:IMM) is an exception. The Company’s lead compound, Lupuzor™, a potential treatment for Lupus, has completed Phase 3 trial of dosing patients across the US, Europe and Mauritius with top line results announced.

To read the full news article please click here

Receive our exclusive interviews – Enter your email to stay up to date.

Disclaimer: Statements in this article should not be considered investment advice, which is best sought directly from a qualified professional.